The Detection of Lactoferrin, ASCA and ANCA in Feces is useful for Assessing Pediatric IBD Patients

James Boone¹, M.S., Darcy Whitlock¹, M.S., Daniel Sisco¹, M.S., Thomas Walker², M.D. and Paul Rufo², M.D. ¹TECHLAB[®], Inc., Blacksburg, Virginia and ²Children's Hospital of Boston, Boston, Massachusetts.

Introduction:

Diagnostic testing for inflammatory bowel disease (IBD) is increasingly common in the clinical setting. More recent immunoassays include fecal lactoferrin (Lf, a marker of intestinal inflammation when elevated), serum anti-Saccharomyces cerevisiae antibodies (ASCA, a marker of Crohn's disease (CD)) and serum antineutrophil cytoplasmic antibodies (ANCA, a marker of ulcerative colitis (UC) and UC-like CD). These assays, as a panel, offer an aid for distinguishing irritable bowel syndrome (IBS) from active IBD, monitoring for inactive and active IBD, and for distinguishing CD from UC and other intestinal illnesses.

<u>Aim:</u>

To evaluate a new diagnostic approach measuring fecal Lf, ASCA and ANCA for the assessment of pediatric IBD.

Method I:

Fecal Lf, ASCA and ANCA levels were determined bv enzyme-linked immunoassays that inlcuded IBD-SCANTM, ASCA-CHEK, and ANCA-CHEK, respectively. All of the tests were from TechLab. The quantitative ELISA test for lactoferrin uses both a capture and conjugated antibody specific to human lactoferrin. The qualitative ELISA tests for ASCA and ANCA use anti-human immunoglobulin antibody (IgG, IgA, IgAsec and IgM) conjugated to HRP and microwells coated with Saccharomyces *cerevisiae* antigens and neutrophil antigens, respectively.

Method II:

Fecal specimens were diluted in the kit diluents and results were determined by measurement of the optical density (OD) at 450nm. Results of \geq 0.200 and 0.150 were considered positive for the presence of fecal ASCA and ANCA, respectively. The levels of Lf were determined using a standard curve and serial 1:10 dilutions of feces. A cutoff of >7.24 µg/mL was used to define elevated Lf.

Subject Population:

A total of 95 fecal specimens was collected at a pediatric IBD clinic from 38 CD subjects, 41 UC subjects and 6 IBS subjects. The control group consisted of 10 healthy subjects. The age range was 2 to 18 years with a male to female ratio of 1.7. Diagnosis and disease activity were assessed clinically.



Results:

Lactoferrin Levels for Subject Groups

Group ID	No. of Assessments	Mean Lactoferrin Level (µg/mL)	SE	P Value
Active IBD	60	2321.7	496.0	Active IBD vs Inactive IBD p < 0.0002
Inactive IBD	19	1.7	0.4	Inactive IBD vs IBS p < 0.9
IBS	6	1.9	1.0	IBS vs active IBD p < 0.0002
нс	10	3.4	1.1	HC vs IBS p < 0.5

James Boone, M.S., TECHLAB [•], Inc., Blacksburg, VA e-mail: jhboone@techlab.com

IBD-FIRST CHEK Panel Results

Total		Flowered	Paralina			
Assessments N = 95	Total	lactoferrin >7.24µg/mL	lactoferrin <7.25µg/mL	N=95	CD	UC/IBS/
Total active IBD	60	60 (100%)	0 (0%)	Fecal ASCA	11	2
Total inactive IBD	19	0 (0%)	19 (100%)	Fecal ASCA	28	54
Total ASCA positive	10	10 (100%)	0 (0%)	negative		
Total ANCA positive	9	5 (55.6%)	4 (44.4%)	N-05	UC.	CD (IDS)
Total ASCA and ANCA	3	3 (100%)	0 (0%)	N-95	UC	HC
positive Total Active IBS	6	0(0%)	100% (6)	Fecal ANCA positive	12	1
Total Healthy Controls	10	2(20%)	8 (80%)	Fecal ANCA negative	29	53

Statistical Analysis of Test Results

	ASCA	ANCA
N=95	CD vs UC IBS	UC vs HC CD IBS HC
Sensitivity	28.21%	6 29.3%
Specificity	96.4%	98.2%
Predictive Pos Value	84.6%	92.3%
Predictive Neg Value	65.9%	64.6%
Correlation	68.4%	68.4%

Group ID	Mean OD	SD	OD Range	P Value
ASCA pos.	1.523	0.796	0.255-2.967	ASCA pos. vs ASCA neg. p < 0.00001
ASCA	0.060	0.033	0.040-0.186	ND
ANCA pos.	0.354	0.187	0.198-0.804	ANCA pos vs ANCA neg p<0.0005
ANCA neg.	0.073	0.030	0.039-0.147	ND
	С	oncl	usion	s:

Results show that fecal Lf, ASCA and ANCA were able to resolve 75.3% of subjects.

•Sensitivity and specificity are similar or better than that reported for serum-based ASCA and ANCA tests in the pediatric IBD population.

•Our results show that the combination of fecal Lf, ASCA and ANCA is useful as a noninvasive and inexpensive diagnostic screen for chronic intestinal illnesses.